Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00758251

Enrollment

Registered

2008-09-25

Start date

2008-09-30

Completion date

2009-03-31

Last updated

2010-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Schizophrenia, Seroquel XR, CGI

Brief summary

The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study * Signed and dated Patient Informed Consent (ICF)

Exclusion criteria

* Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

Design outcomes

Primary

Measure	Time frame
Improvement in CGI scores and BPRS comparing visits 1 and 3.	twice with 4 week interval

Secondary

Measure	Time frame
To evaluate compliance to therapy	twice with 4 week interval

Countries

Latvia

Outcome results